BioCell Technology Announces Positive Top-Line Results for Biocell Collagen II® Arthritis Clinical Study

Share Article

Latest 80 Patient Human Clinical Trial Confirms Earlier Results Demonstrating the Safety and Efficacy of BioCell Collagen II in Supporting OA-Associated Joint Conditions

News Image
Qualitative and quantitative outcomes from this study indicate improvement in pain, stiffness, mobility, and overall improvement in quality of life.

BioCell Technology LLC announces the completion of the largest human study to date of BioCell Collagen II in subjects suffering from joint conditions associated with OA (osteoarthritis). This multi-center, double-blind, placebo-controlled trial has demonstrated the safety and efficacy of BioCell Collagen II in addressing the disease symptoms and in improving various physical activities, as measured by VAS and WOMAC scores.

A previous 16 patient study of BioCell Collagen II had demonstrated a similar safety profile and statistically significant efficacy in supporting chronic degenerative joint conditions in patients with OA. The recently completed study enrolled 80 patients to strengthen the statistical force behind the earlier finding. In addition, the current study investigated the effect of BioCell Collagen II for a longer term than the previous one. This has made possible various statistical analyses, one of whose key findings was that a significant portion of OA patients experienced highly substantial improvement of their joint conditions. The details of this study are expected to be published in the near future.    

"Osteoarthritis is a degenerative joint condition that causes pain and inflammation. It affects over 33 million Americans and is the most common joint disease," said Dr. Joosang Park, vice president of scientific affairs at BioCell Technology. "I am particularly excited about these findings because they confirm earlier studies and offers further support that BioCell Collagen II is a safe and effective alternative to prescription drug products. Qualitative and quantitative outcomes from this study indicate improvement in pain, stiffness, mobility, and overall improvement in quality of life."

"We have always believed in BioCell Collagen II’s potential to make a difference in peoples’ lives. We are pleased with the results of this study and look forward to presenting the full study results,” said Suhail Ishaq, executive vice president of BioCell Technology.

About BioCell Collagen II:

BioCell Collagen II® is a novel dietary ingredient marketed as a healthy aging nutritional supplement that promotes both healthy joints and more youthful-looking skin. It is unique in that it is a naturally-occurring matrix whose three major constituents, collagen type II, chondroitin sulfate, and hyaluronic acid, are reduced to highly-bioavailable, very low molecular weight forms due to its patented hydrolysis process. Made from articular cartilage, its composition is similar to that of human articular joint cartilage.

About BioCell Technology:

Founded in 1997, BioCell Technology, LLC is the exclusive supplier of BioCell Collagen II. BioCell Technology, LLC owns the exclusive rights to market BioCell Collagen II under the United States Patents #6,025,327, 6,323,319, 6,780,841, 7,091,180. BioCell Collagen II is a branded registered logo that is available for display on its client’s labels to market under their own brand name or formulas. For more information on BioCell Collagen II, please contact BioCell Technology, LLC at (714) 632-1231, or visit them at http://www.biocelltechnology.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joosang Park, PhD, MBA
Visit website